FoundationOne / Molecular tumor profiling

FoundationOne®CDx for solid tumors from FFPE biopsies

• Validated NGS-based analysis of the four most important classes of genomic alterations (base substitutions, insertions/deletions, copy number variations and gene combinations).
• Sequencing of the entire coding sequence of 324 genes and introns to determine the fusions of 36 selected genes.
• Determination of Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI).
• The FoundationOne®CDx test is a test approved by the US health authorities for molecular tumor diagnostics.

Comprehensive approach delivers reliable results

• Detects all classes of genetic alterations – base substitutions, insertions/deletions, copy number variations and gene combinations.
• FoundationOne®CDx is a comprehensive tumor profile based on a validation study demonstrating industry-leading accuracy and published in a peer-reviewed scientific journal.

Saves fabric material and time

• Requires only a small amount of tissue, including routine biopsies and fine needle aspirates.
• Also works for samples with a high proportion of non-tumor cells.

Information on ordering FoundationOne®CDx

Order form
Technical specifications
Sample guide CDx

FoundationOneLiquid®CDx for liquid biopsy of solid tumors

• FoundationOne®Liquid CDx detects the four major classes of genomic alterations in 324 cancer-related genes and indicates microsatellite instability (MSI) status and blood tumor mutation burden (bTMB).
• The high specificity and sensitivity ensure that you can rely on the gene alterations found and shown in the report. The tumor fraction indicates the percentage of circulating tumor DNA (ctDNA) in cell-free DNA (cfDNA). This percentage is based on the aneuploid instability observed in the sample. The more abnormal cells present, the higher the tumor fraction
• The FoundationOne(R)CDx test is a text approved by the US health authorities for molecular tumor diagnostics.

Information on ordering FoundationOneLiquid®CDx

Order form
Technical specifications
Sample guide Liquid CDx

FoundationOne®Heme for hematologic diseases and sarcomas

• Validated NGS-based analysis of the four most important classes of genomic alterations (base substitutions, insertions/deletions, copy number variations and gene combinations).
• DNA sequencing of the entire coding sequence of 406 genes and introns to determine fusions from 36 selected genes.
• RNA sequencing of 265 genes that are frequently recombined in the tumor to better identify known and new fusion partners.
• Determination of Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI).
• DNA and RNA sequencing is performed at a median coverage of 500x, analyzing approximately 6.9 million unique base pairs.

Information on ordering FoundationOne®Heme

Order form
Technical specifications
Sample guide Heme

Applicable results summarized in a report

All clinically relevant genetic changes identified are matched with targeted therapies and clinical trial programs based on current scientific knowledge and published clinical data.

Example report FOne®CDx